Login / Signup

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.

Robert S SeitzMichael E HurwitzTyler J NielsenDaniel B BaileyMatthew G VargaBrian Z RingCarrie F MettsBrock L SchweitzerKimberly McGregorDouglas T Ross
Published in: Journal of translational medicine (2022)
The IMvigor210 results demonstrate the potential for the IO Score as a clinically useful biomarker in mUC. As this is the third tumor type assessed using the same algorithm and threshold, the IO Score may be a promising candidate as a tissue agnostic marker of ICI clinical benefit. The concordance between IO Score and inflammatory gene expression suggests that the classifier is capturing common features of the TIME across cancer types.
Keyphrases